Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Goldenberg Gary					2. Issuer Name and Ticker or Trading Symbol Verrica Pharmaceuticals Inc. [VRCA]									neck all app Direc	tor	ng Per	10% Ov	ner	
(Last)	(Fir	st) (MARMACEUTICA	Middle) ALS IN	NC.	3. Date of Earliest Transaction (Month/Day/Year) 08/24/2023										^ belov	Officer (give title below) Chief Medical Officer			
44 WEST GAY STREET, SUITE 400				4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)								
(Street) WEST CHESTE					X Form filed by One Reporting Person Form filed by More than One Reporting Person														
(City)	(Sta	ate) (Z	Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan t satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						n that is inter	nded to							
		Table	I - No	n-Deriva	ative S	Secu	rities	Acq	uired	, Dis	posed of	, or	Ben	eficia	ally Own	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Execution Date		ution I	Date,	Code (Instr						d Securi Benefi	urities leficially ned Following		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amount	(A) or (D)		Price	Transa	action(s) 3 and 4)			(111501.4)	
Common Stock 08/24/2					/2023				A		25,000 ⁽¹⁾)	Α	\$0.0	95,110			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any		ion Date,	4. Transaction Code (Instr. 8)		of Deriv	r osed) r. 3, 4	Expiration Day/\(\text{in}\)		tte Amo (ear) Secu Unde Deriv Secu		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	or Nur of	ount mber ıres					

Explanation of Responses:

1. Represents vesting of shares of common stock underlying performance stock units resulting from the achievement of certain non-financial milestones. These shares have not been delivered.

Remarks:

/s/ Mark Ballantyne, Attorney-08/28/2023 in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.